Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by IFM Investors Pty Ltd

IFM Investors Pty Ltd boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 16.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 214,041 shares of the company’s stock after acquiring an additional 30,270 shares during the quarter. IFM Investors Pty Ltd’s holdings in Teva Pharmaceutical Industries were worth $3,020,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in TEVA. Blue Trust Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after acquiring an additional 2,180 shares during the last quarter. Signaturefd LLC raised its holdings in Teva Pharmaceutical Industries by 90.8% during the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock worth $51,000 after buying an additional 2,394 shares during the period. Psagot Value Holdings Ltd. Israel purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $57,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $82,000. Finally, Desjardins Global Asset Management Inc. increased its position in shares of Teva Pharmaceutical Industries by 15.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after acquiring an additional 1,070 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on TEVA shares. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their target price for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $12.00 to $19.00 in a research note on Monday, February 12th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Finally, Barclays increased their price objective on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.78.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the transaction, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at $132,062.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the transaction, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares of the company’s stock, valued at approximately $1,145,693.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 390,738 shares of company stock valued at $5,132,766. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.56 during midday trading on Friday, hitting $13.81. The company had a trading volume of 10,278,701 shares, compared to its average volume of 8,331,025. The business’s 50 day simple moving average is $13.51 and its two-hundred day simple moving average is $11.39. Teva Pharmaceutical Industries Limited has a 1-year low of $7.09 and a 1-year high of $14.47. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.25. The company had revenue of $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.